PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model

Clinical & Experimental Metastasis, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 5, 2024

Language: Английский

---

Revisiting the CXCL13/CXCR5 Axis in the Tumor Microenvironment in the Era of Single-cell Omics: Implications for Immunotherapy

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217278 - 217278

Published: Sept. 1, 2024

Language: Английский

---

Mathematical modeling predicts optimal immune checkpoint inhibitor and radiotherapy combinations and timing of administration

Cancer Immunology Research, Journal Year: 2024, Volume and Issue: unknown, P. OF1 - OF12

Published: Dec. 12, 2024

Abstract Radiotherapy (RT) combined with immune checkpoint inhibitor (ICI) therapy has attracted substantial attention due to its potential improve outcomes for patients several types of cancer. However, the optimal administration timepoints and drug combinations remain unclear because mechanisms underlying RT-induced changes in molecule expression interaction their ligand(s) unclear. In this study, we demonstrated dynamics lymphocyte-mediated molecular interactions tissue samples from esophageal cancer throughout RT schedules. Single-cell RNA sequencing spatial transcriptomic analyses were performed investigate these interactions. The biological signal lymphocytes transitioned innate adaptive reaction, increases ligand–receptor interactions, such as PD-1–PD-L1, CTLA4–CD80/86, TIGIT–PVR A mathematical model was constructed predict efficacy five ICIs when administered at four different timepoints. suggested that concurrent anti–PD-1/PD-L1 or concurrent/adjuvant anti-CTLA4/TIGIT would exert a maximal effect RT. This study provides rationale clinical trials defined ICI therapy, findings will support future studies search more effective targets timing administration.

Language: Английский

---

Metastatic brain tumors: from development to cutting‐edge treatment

MedComm, Journal Year: 2024, Volume and Issue: 6(1)

Published: Dec. 20, 2024

Abstract Metastatic brain tumors, also called metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the include lung cancer and breast cancer. In recent years, prognosis for BM patients has improved, significant advancements have been made in both clinical preclinical research. This review focuses on originating from We briefly overview history epidemiology BM, as well current diagnostic treatment paradigms. Additionally, we summarize multiomics evidence mechanisms tumor occurrence development era artificial intelligence discuss role microenvironment. Preclinically, introduce establishment models, detailed molecular mechanisms, cutting‐edge methods. is primarily treated with comprehensive approach, including local treatments such surgery radiotherapy. For cancer, targeted therapy immunotherapy shown efficacy, while monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugates are effective BM. Multiomics approaches assist diagnosis treatment, revealing complex Moreover, agents often need cross blood–brain barrier achieve high intracranial concentrations, small‐molecule nanoparticles, peptide drugs. Addressing imperative.

Language: Английский

---

SIGLEC9 tips the myeloid balance in glioblastoma

Nature Cancer, Journal Year: 2023, Volume and Issue: 4(9), P. 1217 - 1219

Published: July 27, 2023

Language: Английский

---